GoodRx Unveils New E-commerce Platform, Launches with Opill®

GDRX 10.31.2024

Full Press ReleaseSEC FilingsOur GDRX Tweets

About Gravity Analytica

Recent News

  • 01.22.2025 - Scott Wagner Joins GoodRx Board of Directors
  • 01.21.2025 - Steven Valiquette
  • 01.15.2025 - Wendy Barnes

Recent Filings

  • 01.22.2025 - 8-K Current report
  • 01.15.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.08.2025 - 3 Initial statement of beneficial ownership of securities
PDF Version

First over-the-counter daily birth control pill now available to order via GoodRx’s new direct-to-consumer shopping experience

SANTA MONICA, Calif.--(BUSINESS WIRE)--Oct. 31, 2024--Today,GoodRx(Nasdaq: GDRX), the leading prescription savings platform in theU.S., announced the rollout of its new e-commerce solution, withOpill®as its launch partner. This new seamless direct-to-consumer shopping experience allows consumers to order eligible health products and medications on theGoodRxplatform and have them shipped directly to their door. Not only does this mark GoodRx’s entry into the over-the-counter (OTC) market, but it offers valuable partnership opportunities for consumer health and pharmaceutical brands looking to leverage GoodRx’s extensive reach and scale.

This press release features multimedia. View the full release here:https://www.businesswire.com/news/home/20241031197282/en/

(Photo: Business Wire)

(Photo: Business Wire)

The introduction of this new e-commerce service is part of GoodRx’s broader strategy to further integrate health and wellness brands into its platform, streamlining the purchasing process and increasing accessibility of essential products and medications. Now, consumers have another way of conveniently ordering Opill contraception directly to their doorsteps without the need for a doctor visit or prescription. This newGoodRxcapability allows consumer health and pharmaceutical brands looking to provide a frictionless experience for consumers to integrate their offerings directly within theGoodRxplatform.

"We are thrilled to launch our e-commerce solution with Opill, an initiative that underscores our mutual commitment to more accessible healthcare," statedDorothy Gemmell, Chief Commercial Officer atGoodRx. "This new feature will provide patients with a simple, seamless way to obtain their eligible medications, building on howGoodRxhas already made prescription medications more affordable and accessible for millions of consumers. It also paves the way for other OTC brands and pharma partners to leverage our platform’s reach to expand market presence, increase consumer access to essential medications and ultimately help drive growth."

TheGoodRxand Opill partnership addresses significant gaps in healthcare access, particularly for themore than 19 millionwomen living in areas with limited contraceptive services. By removing major obstacles such as high costs and logistical challenges, this initiative provides another avenue for direct access to OTC birth control, empowering women to take control of their reproductive health with ease and without a visit to a doctor.

“Perrigo worked for years to bring aU.S.daily oral birth control option over the counter, providing a solution to those experiencing barriers like a lapse in insurance coverage and a historic lack of effective options available without a prescription,” saidSara Young, SVP and Chief Growth and Transformation Officer at Perrigo, the manufacturer of Opill. “Teaming up withGoodRxallows us to leverage its broad user base and easy-to-use platform to make it simple for women to directly order Opill, which is currently the most effective birth control option available without a prescription. This partnership makes accessing birth control more convenient for the millions of people who useGoodRxeach year.”

Leveraging deep insights into consumer health behavior, GoodRx’s new e-commerce experience aligns with the surge in consumer demand for more autonomy over healthcare management, a trend accelerated by the global COVID-19 pandemic. By addressing traditional healthcare hurdles,GoodRxis empowering consumers to manage their healthcare more effectively and independently, and enabling partners to improve visibility and accessibility for their medications.

For Important Safety Information, please seeOpill.comand fullPatient Information

AboutGoodRx

GoodRxis the leading prescription savings platform in theU.S.Trusted by more than 25 million consumers and 750,000 healthcare professionals annually,GoodRxprovides access to savings and affordability options for generic and brand-name medications at more than 70,000 pharmacies nationwide, as well as comprehensive healthcare research and information. Since 2011,GoodRxhas helped consumers save over$75 billionon the cost of their prescriptions.

GoodRxperiodically posts information that may be important to investors on its investor relations website athttps://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with theSecurities and Exchange Commission(the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the expected benefits and value of our partnership with Opill and GoodRx’s e-commerce feature and other offerings; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year endedDecember 31, 2023, and our other filings with theSEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241031197282/en/

Press@GoodRx.com

Source:GoodRx

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com